Aion Therapeutic Inc. (CSE: AION) has secured a worldwide licensing agreement for I2Pure Corp.'s patented molecular iodine technology for water disinfection applications. This agreement enhances Toppen Health's advanced water filtration systems, allowing for the removal of pathogens, PFAS, and pharmaceuticals from any water source. The license includes:
1. A four-year exclusive worldwide license
2. A cash payment of USD $250,000
3. USD $1,000,000 in Aion Therapeutic common shares
4. A 6% royalty fee on transactions using I2Pure's technologies, starting one year after the agreement
The agreement aims to revolutionize water filtration and disinfection, particularly in dental and healthcare industries, by combining Toppen's advanced filtration with I2Pure's molecular iodine technology.
Aion Therapeutic Inc. (CSE: AION) announces patent filings by its subsidiary, Toppen Health, for innovative water filtration technology. The patented Center Core technology eliminates the need for testing, ensuring 99.9999% clean water by releasing molecular iodine safely and effectively. This cost-effective solution addresses water quality issues in healthcare, particularly dental, and beyond. The technology promises to revolutionize water safety globally.
Summary not available.
Summary not available.
Summary not available.